Importantly, KRB-456 is effective at thwarting the in vivo growth of subcutaneous and orthotopic tumors from pancreatic cancer patients with mt KRAS G12D and G12V who have relapsed after chemotherapy and radiotherapy. This evidence concerns the gene KRAS and familial pancreatic carcinoma.